Article Figures & Data
Figures
- Figure 1
Four-quadrant biopsies are taken every 2 cm, plus at any mucosal irregularities in salmon-colored mucosa above the gastroesophageal junction.
- Figure 2
A: Endoscopic picture of Barrett esophagus with arrow pointing to nodule. B: After endoscopic mucosal resection of nodule. C: Barrett esophagus before radiofrequency ablation. D: Barrett esophagus after ablation.
Tables
Nondysplastic Barrett esophagus AGA, ACG, and ASGE recommend surveillance every 3–5 years ‘Indefinite for dysplasia’ AGA: no recommendation ACG: repeat esophagogastroduodenoscopy (EGD) after 3–6 months of proton pump inhibitor (PPI) therapy; if repeat EGD indicates “indefinite for dysplasia,” then surveillance every 12 months ASGE: additional pathology review, PPI dose escalation, and repeat EGD with biopsy Low-grade dysplasia AGA: surveillance every 6–12 months ACG: either endoscopic eradication therapy for confirmed low-grade dysplasia for patients without a life-limiting comorbidity, or surveillance every 12 months ASGE: repeat EGD in 6 months to confirm low-grade dysplasia, then surveillance every year, with eradication therapy in select patients High-grade dysplasia AGA: eradication therapy or surveillance every 3 months ACG: eradication therapy for confirmed high-grade dysplasia in patients without a life-limiting comorbidity ASGE: eradication therapy or surveillance every 3 months ↵a All guidelines recommend confirmation of dysplasia by an expert gastrointestinal pathologist.
ACG = American College of Gastroenterology4; AGA = American Gastroenterological Association24; ASGE = American Society for Gastrointestinal Endoscopy23
Jump to section
- Article
- ABSTRACT
- SCOPE OF THE PROBLEM
- GASTROESOPHAGEAL REFLUX DISEASE IS A RISK FACTOR FOR CANCER
- RISK FACTORS FOR BARRETT ESOPHAGUS
- SCREENING GUIDELINES AND DRAWBACKS
- SURVEILLANCE: WHAT’S INVOLVED, WHAT’S AVAILABLE
- MANAGEMENT OF NONDYSPLASTIC BARRETT ESOPHAGUS
- DOES CHEMOPREVENTION HAVE A ROLE?
- INDEFINITE DYSPLASIA
- ENDOSCOPIC ERADICATION: AN OVERVIEW
- LOW-GRADE DYSPLASIA: RECOMMENDED MANAGEMENT
- HIGH-GRADE DYSPLASIA: RECOMMENDED MANAGEMENT
- EARLY ESOPHAGEAL ADENOCARCINOMA: RECOMMENDED MANAGEMENT
- POSTABLATION MANAGEMENT
- References
- Figures & Data
- Info & Metrics